Recent developments in cancer treatment have shown promising results as researchers explore new immunotherapy techniques that could benefit a range of cancer types. Innovations include the use of antibody-lectin chimeras for glyco-immune checkpoint blockade and the development of protein therapies targeting tumor cell sugar mechanisms. Notably, a clinical trial has demonstrated the effectiveness of new immunotherapy strategies against drug-resistant tumors. Additionally, bispecific antibodies are emerging as dual agents capable of addressing both hematological malignancies and solid tumors. MD Anderson has also unveiled significant breakthroughs in blood cancer treatment, emphasizing the increasing focus on targeting glycans and using zinc finger proteins to enhance tumor immunity. These advancements highlight the potential of new ‘plug-and-play’ immunotherapeutic approaches to significantly improve treatment outcomes for common cancers.